Genetics

Scientists recently explored whether certain genetic variations in the IL28B gene—known to predict treatment success in hepatitis C—could also forecast how well people with multiple sclerosis (MS) respond to interferon-beta, a common MS therapy. Analyzing data from 588 patients across multiple countries, researchers found no meaningful link between these gene variants and treatment outcomes, suggesting that IL28B isn't a reliable predictor for MS therapy response. While one subgroup showed a hint of a connection, the overall results highlight just how complex MS is and remind us that personalized medicine in this field still has a long way to go.